粪便免疫化学检测在Lynch综合征中检出结直肠肿瘤:一项前瞻性多中心研究
这项前瞻性多中心观察性研究纳入217例Lynch综合征个体,在高质结肠镜监测前完成定量粪便免疫化学检测(FIT)。以2.5 μg Hb/g粪便为阳性阈值时,对结直肠癌(CRC)加进展期腺瘤(AA)的敏感性和阴性预测值分别为89%和99%,对进展期肿瘤为69%和97%,对全部相关肿瘤为26%和72%,所有组特异性均为91%。阈值4.1 μg/g时进展期肿瘤特异性优化至94%。作者认为FIT阈值≤4.1 μg Hb/g粪便可能是有前景的策略,可使约10例Lynch综合征个体中的9例推迟结肠镜。
要点
- 纳入217例Lynch综合征个体,FIT阈值2.5 μg Hb/g粪便时CRC加AA敏感性89%、阴性预测值99%。
- 阈值2.5 μg Hb/g粪便时进展期肿瘤敏感性69%、阴性预测值97%,全部相关肿瘤敏感性26%、阴性预测值72%。
- 阈值4.1 μg/g时进展期肿瘤特异性94%,每100次FIT中11例阳性、2例进展期肿瘤被漏诊。
核心结论
- FIT阈值≤4.1 μg Hb/g粪便可能是有前景的策略,可使约10例Lynch综合征个体中的9例推迟结肠镜。
- 作者认为应优先开展大型验证研究并提供基因变异特异性结果。
研究设计与样本
- 前瞻性、多中心观察性研究,Lynch综合征个体在高质监测结肠镜前完成定量FIT。
- 共纳入217例个体,59%为女性,中位年龄51岁。
- 评估FIT在≤20 μg Hb/g粪便各阈值下对相关肿瘤的诊断性能。
主要发现
- 217例中CRC 4例、AA 5例、ASL 4例、NAA 57例为最相关肿瘤。
- 最低FIT阳性阈值2.5 μg Hb/g粪便(阳性率14%)检出4/4 CRC、4/5 AA、1/4 ASL、9/57 NAA。
- 阈值2.5 μg Hb/g粪便时CRC加AA敏感性89%、阴性预测值99%,进展期肿瘤69%和97%,全部相关肿瘤26%和72%,所有组特异性91%。
- 在相同敏感性和阴性预测值下,阈值4.1 μg/g时进展期肿瘤特异性优化至94%。
- 阈值4.1 μg/g时每100次FIT中11例阳性并接受结肠镜,2例进展期肿瘤被漏诊,需3例结肠镜检出1例进展期肿瘤。
局限性
- 作者认为应优先开展大型验证研究,并提供基因变异特异性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Colonoscopy surveillance for Lynch syndrome is burdensome and postcolonoscopy colorectal cancers (CRCs) still occur. The noninvasive fecal immunochemical test (FIT) might guide optimal colonoscopy intervals. METHODS: Prospective, multicenter observational study in which individuals with Lynch syndrome performed a quantitative FIT before high-quality surveillance colonoscopy. Diagnostic performance of FIT at various thresholds ≤20 μg Hb/g feces was assessed for relevant neoplasia, including advanced neoplasia (CRC, advanced adenomas [AAs] and advanced serrated lesions [ASLs]) and non-advanced adenomas (NAAs). RESULTS: Of the 217 included individuals (59% female, median age 51 years), 4 had CRC, 5 AA, 4 ASL, and 57 NAA as most relevant neoplasia. The lowest FIT positivity threshold (2.5 μg Hb/g feces, 14% positivity rate) maximized detection: 4/4 CRCs, 4/5 AA, 1/4 ASL, and 9/57 NAA were detected, resulting in a sensitivity and negative predictive value of, respectively, 89% and 99% for CRC plus AA, 69% and 97% for advanced neoplasia, and 26% and 72% for all relevant neoplasia (91% specificity for all groups). At equal sensitivity and negative predictive value, specificity for advanced neoplasia optimized to 94% at threshold 4.1 μg/g. Per 100 FITs at threshold 4.1 μg/g, 11 individuals would test positive and thus proceed to colonoscopy, 2 individuals with advanced neoplasia would be missed and 3 individuals would need colonoscopy to detect 1 advanced neoplasia. DISCUSSION: FIT at thresholds ≤4.1 μg Hb/g feces may be a promising strategy to postpone colonoscopy in approximately 9 of 10 individuals with Lynch syndrome. Large validation studies that also provide gene variant-specific outcomes should be prioritized.
引用
- van Liere ELSA, de Boer NKH, van Leerdam ME, et al. Fecal Immunochemical Test to Detect Colorectal Neoplasia in Lynch Syndrome: A Prospective Multicenter Study. Am J Gastroenterol. 2024. PMID: 39162771. doi:10.14309/ajg.0000000000003043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。